Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684648 | 0.86 | POLB (0.50) | POLBDHFRKDM4EALDH1A1CSF1R | |
| SCHEMBL12989454 | 0.85 | NPC1 (0.41) | POLBKDM4EMEN1KMT2ATP53 | |
| SCHEMBL14711183 | 0.85 | LPAR1 (0.48) | POLBALDH1A1HPGDKMT2ALPAR1 | |
| SCHEMBL15897047 | 0.85 | TPMT (0.37) | POLBDHFRKDM4EALDH1A1HPGD | |
| SCHEMBL25340747 | 0.80 | TDP1 (0.44) | POLBKDM4EALDH1A1KMT2ARAB9A | |
| SCHEMBL20027814 | 0.80 | SMN1; SMN2 (0.55) | ALDH1A1MEN1KMT2ALMNATP53 | |
| SCHEMBL28469826 | 0.80 | KMO (0.44) | — | |
| SCHEMBL462903 | 0.77 | HSD11B1 (0.45) | KDM4EALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL29272612 | 0.77 | SMN1; SMN2 (0.40) | KDM4EALDH1A1HPGDPTGER4MEN1 | |
| SCHEMBL23294499 | 0.76 | KMO (0.46) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022234271-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-11-10 | — | — | WO | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| EP-2870141-B1 | METHANETHIONE COMPOUNDS HAVING ANTIVIRAL ACTIVITY | VIRONOVA INFLUENZA AB (SE) | 2017-11-22 | — | — | EP | disclosed |
| US-9676734-B2 | Compounds and methods | VIRONOVA INFLUENZA AB (SE) | 2017-06-13 | — | — | US | disclosed |
| US-9676734-B2 | Compounds and methods | VIRONOVA INFLUENZA AB (SE) | 2017-06-13 | — | — | US | disclosed |
| US-20160280669-A1 | COMPOUNDS AND METHODS | VIRONOVA INFLUENZA AB (SE) | 2016-09-29 | — | — | US | disclosed |
| US-9359310-B2 | Methanethione compounds having antiviral activity | VIRONOVA INFLUENZA AB (SE) | 2016-06-07 | — | — | US | disclosed |
| US-20150133468-A1 | METHANETHIONE COMPOUNDS HAVING ANTIVIRAL ACTIVITY | VIRONOVA AB (SE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | POLB 2724/4885DHFR 3918/4885KDM4E 3495/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | POLB 2408/4885DHFR 4126/4885KDM4E 3117/4885 |
| US-20150133468-A1 | METHANETHIONE COMPOUNDS HAVING ANTIVIRAL ACTIVITY | MAVS, EIF2AK2, STING1 | POLB 376/4885DHFR 1760/4885KDM4E 3277/4885 |
| US-20160280669-A1 | COMPOUNDS AND METHODS | EIF2AK2, ZC3HAV1, HIF1AN | POLB 92/4885DHFR 1100/4885KDM4E 4199/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | POLB 2724/4885DHFR 3918/4885KDM4E 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.